$0.73
5.68% yesterday
Nasdaq, May 20, 10:04 pm CET
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Neumora Therapeutics Stock price

$0.73
+0.07 10.56% 1M
-9.06 92.55% 6M
-9.87 93.12% YTD
-8.96 92.47% 1Y
-16.27 95.71% 3Y
-16.27 95.71% 5Y
-16.27 95.71% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.04 5.68%
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Key metrics

Market capitalization $118.03m
Enterprise Value $-131.60m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.66
P/B ratio (TTM) P/B ratio 0.52
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-274.33m
Free Cash Flow (TTM) Free Cash Flow $-199.43m
Cash position $250.57m
EPS (TTM) EPS $-1.61
P/E forward negative
Short interest 21.84%
Show more

Is Neumora Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Neumora Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Neumora Therapeutics forecast:

3x Buy
38%
5x Hold
63%

Analyst Opinions

8 Analysts have issued a Neumora Therapeutics forecast:

Buy
38%
Hold
63%

Financial data from Neumora Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.63 0.63
73% 73%
-
-0.63 -0.63
73% 73%
-
- Selling and Administrative Expenses 66 66
45% 45%
-
- Research and Development Expense 207 207
30% 30%
-
-274 -274
32% 32%
-
- Depreciation and Amortization 0.63 0.63
73% 73%
-
EBIT (Operating Income) EBIT -274 -274
31% 31%
-
Net Profit -258 -258
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neumora Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neumora Therapeutics Stock News

Neutral
PRNewsWire
6 days ago
NEW YORK , May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumo...
Neutral
Seeking Alpha
8 days ago
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q1 2025 Results Conference Call May 12, 2025 4:30 PM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Mike Milligan - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wain...
Neutral
GlobeNewsWire
8 days ago
On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-20...
More Neumora Therapeutics News

Company Profile

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Head office United States
CEO Paul Berns
Employees 110
Founded 2019
Website www.neumoratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today